Suppression_NN of_IN Growth_NN by_IN All-trans_NP Retinoic_NP Acid_NP Requires_NP Prolonged_NP Induction_NP of_IN Interferon_NP Regulatory_NP Factor_NP 1_CD in_IN Cervical_NP Squamous_NP Carcinoma_NP (_( SiHa_NP )_) Cells_NP All-trans_NP retinoic_JJ acid_NN (_( ATRA_NP )_) suppresses_VBZ growth_NN of_IN cervical_JJ dysplasias_NNS in_IN vivo_RB ,_, although_IN the_DT sensitivity_NN to_TO retinoids_NNS is_VBZ frequently_RB lost_VBN during_IN cervical_JJ carcinogenesis_NN ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN prolonged_JJ treatment_NN or_CC use_NN of_IN higher_JJR doses_NNS of_IN retinoids_NNS might_MD offer_VB favorable_JJ response_NN rates_NNS ._SENT We_PP found_VBD SiHa_NP cervical_JJ squamous_JJ carcinoma_NN cells_NNS that_WDT were_VBD virtually_RB resistant_JJ to_TO ATRA-induced_JJ growth-inhibitory_JJ effects_NNS at_IN physiological_JJ doses_NNS (_( 10-7_CD to_TO 10-6_CD M_NN )_) to_TO be_VB more_RBR responsive_JJ at_IN pharmacological_JJ doses_NNS (_( 10-5_CD to_TO 10-4_CD M_NN )_) ._SENT The_DT growth_NN inhibition_NN by_IN high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP was_VBD associated_VBN with_IN a_DT sustained_JJ activation_NN of_IN interferon_NN regulatory_JJ factor_NN 1_CD (_( IRF-1_NP )_) ,_, while_IN a_DT low_JJ dose_NN (_( 10-6_CD M_NN )_) of_IN ATRA_NP activated_VBD IRF-1_NP only_RB transiently_RB ._SENT Antisense_NN IRF-1_NP inhibited_VBD the_DT high-dose_NN (_( 10-4_CD M_NP )_) ,_, ATRA-mediated_JJ growth_NN arrest_NN ;_: forced_VBN expression_NN of_IN IRF-1_NP caused_VBD a_DT significant_JJ reduction_NN in_IN cell_NN growth_NN ._SENT High-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP increased_VBD binding_VBG of_IN NF-kappaB_NP and_CC STAT1_NP proteins_NNS to_TO sequences_NNS that_WDT originated_VBP from_IN the_DT IRF-1_JJ promoter_NN region_NN ,_, while_IN low-dose_NN (_( 10-6_CD M_NP )_) ATRA_NP induced_VBD only_JJ NF-kappaB_NP binding_NN ._SENT A_DT delayed_JJ tyrosine_NN phosphorylation_NN of_IN the_DT signal_NN transducer_NN and_CC activator_NN of_IN transcription-1_JJ (_( STAT1_NP )_) was_VBD observed_VBN after_IN high-dose_NN (_( 10-4_CD M_NN )_) but_CC not_RB low-dose_NN (_( 10-6_CD M_NP )_) ATRA_NP treatment_NN ._SENT In_IN agreement_NN with_IN this_DT ,_, induction_NN of_IN IRF-1_JJ mRNA_NN by_IN ATRA_NP was_VBD only_RB modest_JJ and_CC transient_JJ in_IN a_DT STAT1_NP knockout_NN cell_NN line_NN ,_, suggesting_VBG the_DT importance_NN of_IN STAT1_NP in_IN sustained_JJ IRF-1_JJ expression_NN ._SENT Our_PP$ data_NNS showed_VBD that_IN ATRA_NP is_VBZ capable_JJ of_IN inducing_VBG dose-dependent_JJ cellular_JJ changes_NNS ,_, which_WDT might_MD be_VB appropriate_JJ to_TO overcome_VB resistance_NN to_TO retinoids_NNS that_WDT frequently_RB develops_VBZ during_IN cervical_JJ carcinogenesis_NN ._SENT Vitamin_NN A_NP and_CC its_PP$ natural_JJ or_CC synthetic_JJ derivatives_NNS (_( collectively_RB known_VBN as_IN retinoids_NNS )_) are_VBP potent_JJ regulators_NNS of_IN growth_NN of_IN various_JJ malignancies_NNS ,_, including_VBG cervical_JJ cancer_NN ._SENT In_IN clinical_JJ trials_NNS ,_, ATRA_NP could_MD reverse_VB or_CC suppress_VB low-grade_NN or_CC moderate-_NN to_TO high-grade_JJ cervical_JJ dysplasias_NNS ._SENT However_RB ,_, retinoids_NNS were_VBD not_RB effective_JJ in_IN patients_NNS with_IN more_JJR advanced_JJ dysplasias_NNS ;_: this_DT finding_NN is_VBZ similar_JJ to_TO the_DT resistance_NN to_TO ATRA_NP observed_VBN with_IN HPV16-transformed_JJ cervical_JJ keratinocytes_NNS in_IN vitro_NN ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN prolonged_JJ treatment_NN or_CC use_NN of_IN higher_JJR doses_NNS of_IN retinoids_NNS might_MD offer_VB a_DT favorable_JJ response_NN rate_NN ._SENT Retinoids_NNS are_VBP potent_JJ modulators_NNS of_IN cellular_JJ proliferation_NN and_CC differentiation_NN ._SENT In_IN cervical_JJ carcinoma_NN cells_NNS ,_, retinoic_JJ acid_NN induces_VBZ interferon_NN regulatory_JJ factor_NN (_( IRF-1_NP )_) ,_, which_WDT is_VBZ responsible_JJ for_IN growth_NN arrest_NN ._SENT In_IN growth-arrested_JJ cells_NNS ,_, IRF-1_JJ mRNA_NN expression_NN is_VBZ markedly_RB elevated_JJ ,_, but_CC its_PP$ expression_NN declines_VBZ prior_RB to_TO and_CC during_IN DNA_NN synthesis_NN :_: in_IN this_DT context_NN ,_, IRF-1_NP is_VBZ a_DT tumor_NN suppressor_NN ._SENT IRF-1_JJ expression_NN can_MD be_VB stimulated_VBN by_IN ATRA_NP at_IN the_DT level_NN of_IN transcription_NN through_IN a_DT gamma_NN interferon-activated_JJ site_NN (_( GAS_NP )_) ,_, via_IN an_DT NF-kappaB_NP site_NN ,_, or_CC directly_RB via_IN a_DT retinoid-responsive_JJ element_NN found_VBN in_IN the_DT promoter_NN of_IN the_DT IRF-1_JJ gene_NN ._SENT Accordingly_RB ,_, our_PP$ aim_NN was_VBD to_TO determine_VB the_DT effects_NNS of_IN different_JJ doses_NNS of_IN ATRA_NP on_IN the_DT expression_NN and_CC regulation_NN of_IN IRF-1_NP and_CC on_IN the_DT subsequent_JJ inhibition_NN of_IN growth_NN in_IN cervical_JJ squamous_JJ carcinoma_NN (_( SiHa_NP )_) cells_NNS ._SENT Cell_NN lines_NNS ._SENT |_SYM The_DT HPV16-positive_JJ cervical_JJ squamous_JJ carcinoma_NN cell_NN line_NN (_( SiHa_NP )_) was_VBD purchased_VBN from_IN ATCC_NP and_CC maintained_VBN at_IN 37C_JJ in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP medium_NN supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT 2fTGH_NP and_CC U3A_NP fibroblast_NN cell_NN lines_NNS were_VBD gifts_NNS from_IN George_NP Stark_NP (_( The_DT Cleveland_NP Clinic_NP Foundation_NP Research_NP Center_NP ,_, Cleveland_NP ,_, Ohio_NP )_) ,_, and_CC they_PP were_VBD maintained_VBN at_IN 37C_JJ in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP medium_NN supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN plus_CC 250_CD mug_NN of_IN hygromycin/ml_NN in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Plasmids_NNS ._SENT |_SYM The_DT expression_NN vector_NN that_WDT contains_VBZ IRF-1_JJ cDNA_NN (_( pHuIRF3-1_NN )_) was_VBD kindly_RB provided_VBN by_IN Tadatsugu_NP Taniguchi_NP (_( Department_NP of_IN Immunology_NP ,_, Graduate_NP School_NP of_IN Medicine_NP and_CC Faculty_NP of_IN Medicine_NP ,_, University_NP of_IN Tokyo_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT The_DT IRF-1_JJ cDNA_NN was_VBD PCR_NP amplified_VBN and_CC subcloned_VBN into_IN the_DT pCR3.1_JJ bidirectional_JJ eukaryotic_JJ TA_NP cloning_VBG vector_NN (_( Invitrogen_NP ,_, Carlsbad_NP ,_, Calif._NP )_) in_IN both_DT sense_NN and_CC antisense_NN orientations_NNS ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Antibodies_NNS ._SENT |_SYM Anti-STAT1_JJ and_CC anti-phospho-STAT1_JJ antibodies_NNS were_VBD purchased_VBN from_IN Upstate_NP Biochemical_NP ,_, Inc._NP (_( Lake_NP Placid_NP ,_, N.Y._NP )_) ._SENT The_DT anti-IRF-1_JJ antibody_NN was_VBD purchased_VBN from_IN Santa_NP Cruz_NP Biotechnology_NP ,_, Inc._NP (_( Santa_NP Cruz_NP ,_, Calif._NP )_) ._SENT MTT_NP assay_NN ._SENT |_SYM The_DT growth_NN rates_NNS of_IN cells_NNS were_VBD measured_VBN with_IN the_DT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium_JJ bromide_NN (_( MTT_NP )_) assay_NN ._SENT Briefly_RB ,_, 2_CD x_SYM 103_CD cells_NNS in_IN 0.2_CD ml_NN of_IN culture_NN medium_NN were_VBD plated_VBN in_IN each_DT well_NN of_IN a_DT 96-well_NP culture_NN plate_NN ._SENT A_DT total_NN of_IN 10_CD wells_NNS per_IN time_NN point_NN were_VBD used_VBN for_IN treatment_NN ._SENT Cells_NNS were_VBD analyzed_VBN at_IN regular_JJ intervals_NNS of_IN 2_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, and_CC 10_CD days_NNS by_IN the_DT addition_NN of_IN 40_CD mul_NN of_IN MTT_NP ,_, 1.25_CD mug_NN of_IN MTT/ml_NP of_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) ,_, to_TO each_DT well_NN of_IN the_DT plate_NN ._SENT The_DT cells_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 2.5_CD h_NN ,_, the_DT medium_NN was_VBD aspirated_VBN ,_, and_CC the_DT cells_NNS were_VBD then_RB lysed_VBN in_IN 100_CD mul_NN of_IN dimethyl_NN sulfoxide_NN ._SENT Conversion_NN of_IN MTT_NP to_TO formazan_NN by_IN metabolically_RB viable_JJ cells_NNS was_VBD monitored_VBN at_IN 570_CD nm_NN in_IN an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN reader_NN ,_, and_CC the_DT results_NNS were_VBD analyzed_VBN by_IN regression_NN analysis_NN from_IN triplicate_JJ experiments_NNS ._SENT Western_JJ blot_NN analysis_NN ._SENT |_SYM Cells_NP were_VBD washed_VBN ,_, scraped_VBN in_IN PBS_NP ,_, and_CC then_RB centrifuged_VBN ._SENT The_DT pellet_NN was_VBD resuspended_VBN in_IN a_DT RIPA_NP buffer_NN containing_VBG protease_NN inhibitors_NNS and_CC kept_VBN on_IN ice_NN for_IN 60_CD min_NN ._SENT After_IN centrifugation_NN the_DT protein_NN content_NN of_IN the_DT supernatant_JJ (_( whole-cell_NN extract_NN )_) was_VBD determined_VBN by_IN a_DT Bio-Rad_NP DC_NP (_( Hercules_NP ,_, Calif._NP )_) method_NN ._SENT Fifty_CD micrograms_NNS of_IN whole-cell_NN extract_NN was_VBD analyzed_VBN by_IN standard_JJ methods_NNS on_IN a_DT sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN as_RB described_VBD earlier_RBR ._SENT Proteins_NNS were_VBD transferred_VBN to_TO a_DT polyvinylidene_JJ difluoride_NN membrane_NN (_( Bio-Rad_NP )_) and_CC incubated_VBN with_IN the_DT primary_JJ antibody_NN at_IN 4C_JJ overnight_JJ ._SENT Protein_NN bands_NNS were_VBD detected_VBN by_IN an_DT enhanced_JJ chemiluminescent_JJ method_NN (_( ECL_NP ;_: Amersham_NP Pharmacia_NP ,_, Piscataway_NP ,_, N.J._NP )_) ._SENT Bands_NNS were_VBD analyzed_VBN on_IN an_DT AlphaImager_NP system_NN (_( Alpha_NP Innotech_NP ,_, San_NP Leandro_NP ,_, Calif._NP )_) ._SENT Blots_NNS were_VBD stripped_VBN and_CC reprobed_VBN several_JJ times_NNS ._SENT Equal_JJ protein_NN loads_NNS were_VBD checked_VBN by_IN rehybridizing_VBG the_DT blots_NNS with_IN a_DT glyceraldehyde-3-phosphate_NN dehydrogenase_NN (_( G3PDH_NP )_) antibody_NN (_( Advanced_NP Immunochemical_NP ,_, Long_NP Beach_NP ,_, Calif._NP )_) that_WDT served_VBD as_IN a_DT constitutively_RB expressed_VBN internal_JJ control_NN ._SENT RNA_NP isolation_NN and_CC semiquantitative_JJ reverse_JJ transcription-PCR_NN ._SENT |_SYM Cells_NP were_VBD washed_VBN with_IN PBS_NP and_CC directly_RB lysed_VBN in_IN TriReagent-LS_NP (_( Molecular_NP Research_NP Center_NP ,_, Inc._NP ,_, Cincinnati_NP ,_, Ohio_NP )_) and_CC precipitated_VBD according_VBG to_TO the_DT manufacturer_NN 's_POS recommendations_NNS ._SENT One_CD microgram_NN of_IN RNA_NP was_VBD reverse_NN transcribed_VBN (_( SuperScript_NP II_NP ;_: Gibco/BRL_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) and_CC subjected_VBN to_TO PCR_NP amplification_NN as_RB described_VBD earlier_RBR ._SENT Primers_NNS for_IN IRF-1_NP were_VBD custom_NN designed_VBN and_CC synthesized_VBN (_( Genosys_NP ,_, The_DT Woodlands_NP ,_, Tex._NP )_) ._SENT Primers_NNS for_IN G3PDH_NP were_VBD purchased_VBN from_IN Clontech_NP (_( Palo_NP Alto_NP ,_, Calif._NP )_) ._SENT PCR_NP fragments_NNS were_VBD resolved_VBN by_IN agarose_JJ gel_NN electrophoresis_NN and_CC transferred_VBN to_TO a_DT nylon_NN membrane_NN (_( Amersham_NP Pharmacia_NP ,_, Piscataway_NP ,_, N.J._NP )_) and_CC hybridized_VBN with_IN end-labeled_JJ oligonucleotide_NN probes_NNS ._SENT Oligonucleotide_NN probes_NNS were_VBD custom_NN designed_VBN and_CC synthesized_VBN ._SENT Autoradiograms_NNS were_VBD analyzed_VBN by_IN densitometry_NN (_( AlphaImager_NP ;_: Alpha_NP Innotech_NP ,_, San_NP Leandro_NP ,_, Calif._NP )_) ._SENT Electrophoretic_JJ mobility_NN shift_NN assay_NN (_( EMSA_NP )_) ._SENT |_SYM Nuclear_NP extracts_VBZ were_VBD prepared_VBN by_IN lysing_VBG cells_NNS in_IN a_DT buffer_NN containing_VBG 10_CD mM_NP HEPES_NP (_( pH_NN 7.9_CD )_) ,_, 60_CD mM_NP KCl_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, 1_CD mM_NP EDTA_NP ,_, 0.5_CD %_NN NP-40_NN ,_, and_CC 1_CD mM_NP phenylmethylsulfonyl_NN difluoride_NN ._SENT Five_CD to_TO ten_CD micrograms_NNS of_IN nuclear_JJ extracts_VBZ were_VBD incubated_VBN in_IN a_DT binding_JJ buffer_NN (_( 10_CD mM_NP Tris-HCl_NP [_SYM pH_NN 7.6_CD ]_SYM ,_, 50_CD mM_NP KCl_NP ,_, 5_CD mM_NP MgCl2_NP ,_, 0.1_CD mM_NP EDTA_NP ,_, 6_CD %_NN glycerol_NN ,_, 1_CD mM_NP dithiothreitol_NN ,_, 1_CD mug_NN of_IN polydIC_JJ )_) in_IN the_DT presence_NN or_CC absence_NN of_IN a_DT 100-fold_JJ molar_JJ excess_NN of_IN unlabeled_JJ competitor_NN DNA_NN and/or_CC appropriate_JJ antibodies_NNS on_IN ice_NN for_IN 10_CD min_NN ._SENT Following_VBG incubation_NN ,_, 10,000_CD cpm_NN of_IN 32P-end-labeled_JJ oligonucleotide_NN probe_NN was_VBD added_VBN and_CC the_DT reaction_NN was_VBD incubated_VBN at_IN room_NN temperature_NN for_IN an_DT additional_JJ 30_CD min_NN ._SENT The_DT DNA-protein_NP complexes_NNS were_VBD separated_VBN from_IN free_JJ probe_NN by_IN electrophoresis_NN on_IN a_DT 4_CD to_TO 6_CD %_NN polyacrylamide_NN gel_NN ._SENT The_DT gel_NN was_VBD dried_VBN and_CC subjected_VBN to_TO autoradiography_NN ._SENT Oligonucleotides_NNS were_VBD custom_NN designed_VBN and_CC synthesized_VBN (_( Genosys_NP ,_, Inc._NP )_) ._SENT Annealing_VBG of_IN individual_JJ oligonucleotides_NNS was_VBD done_VBN according_VBG to_TO standard_JJ protocols_NNS ._SENT EMSA_NN oligonucleotides_NNS ._SENT |_SYM For_IN gel_NN shift_NN competitions_NNS and_CC experiments_NNS ,_, the_DT following_VBG double-stranded_JJ oligonucleotides_NNS were_VBD used_VBN ._SENT (_( The_DT sense_NN strand_NN is_VBZ shown_VBN ._SENT The_DT oligonucleotides_NNS were_VBD synthesized_VBN by_IN Genosys_NP ,_, Inc._NP ,_, and_CC annealed_VBD according_VBG to_TO a_DT standard_JJ protocol_NN ._SENT )_) IRF1-NF-kappaB_NP ,_, TTAGCGGGATTCCCCAGCCCT_NP ;_: IRF1-GAS_NN ,_, AGCCTGATTTCCCCGAAATGAC_NP ._SENT Plasmid_NP transfection_NN ._SENT Cells_NNS were_VBD transfected_VBN with_IN the_DT recombinant_JJ IRF-1_JJ plasmid_NN using_VBG a_DT GenePORTER_NP 2_CD transfection_NN reagent_NN (_( GTS_NP Inc._NP ,_, San_NP Diego_NP ,_, Calif._NP )_) ._SENT Cells_NNS were_VBD plated_VBN at_IN 5_CD x_SYM 105_CD cells/60-mm_NP dish_NN density_NN in_IN 1_CD ml_NN of_IN culture_NN medium_NN 24_CD h_NN before_IN the_DT transfection_NN so_RB that_IN they_PP will_MD be_VB 60_CD to_TO 90_CD %_NN confluent_NN on_IN the_DT day_NN of_IN transfection_NN ._SENT Then_RB ,_, 4_CD mug_NN of_IN plasmid_NP DNA_NP was_VBD diluted_VBN in_IN 80_CD mul_NN of_IN serum-free_JJ medium_NN plus_CC 20_CD mul_NN of_IN GenePorter_NP 2_CD ,_, which_WDT gives_VBZ a_DT final_JJ volume_NN of_IN 100_CD mul_NN ._SENT This_DT mixture_NN was_VBD incubated_VBN at_IN room_NN temperature_NN for_IN 10_CD min_NN and_CC then_RB was_VBD added_VBN to_TO the_DT cells_NNS ._SENT After_IN 24_CD h_NN ,_, fresh_JJ medium_NN was_VBD added_VBN ._SENT Transfections_NNS were_VBD made_VBN in_IN triplicate_NN ._SENT Controls_NNS such_JJ as_IN mock-transfected_JJ and_CC vector-transfected_JJ cells_NNS were_VBD included_VBN ._SENT ATRA_NP inhibits_VBZ growth_NN of_IN SiHa_NP cells_NNS in_IN a_DT dose-dependent_JJ fashion_NN ._SENT |_SYM SiHa_NP cells_NNS were_VBD grown_VBN in_IN the_DT presence_NN or_CC absence_NN of_IN ATRA_NP for_IN various_JJ time_NN points_NNS ._SENT Cell_NN growth_NN was_VBD determined_VBN by_IN an_DT MTT_NP assay_NN ._SENT Apparently_RB ,_, physiological_JJ (_( low_JJ )_) doses_NNS (_( 10-7_CD and_CC 10-6_CD M_NN )_) of_IN ATRA_NP did_VBD not_RB inhibit_VB cell_NN growth_NN significantly_RB ,_, while_IN administration_NN with_IN pharmacological_JJ (_( high_JJ )_) doses_NNS (_( 10-5_CD and_CC 10-4_CD M_NN )_) of_IN ATRA_NP caused_VBD significant_JJ growth_NN inhibition_NN ._SENT IRF-1_NP participates_VBZ in_IN ATRA-induced_JJ growth_NN inhibition_NN ._SENT |_SYM IRF-1_NP is_VBZ an_DT important_JJ regulator_NN of_IN cell_NN proliferation_NN ,_, so_RB its_PP$ role_NN in_IN ATRA-induced_JJ growth_NN inhibition_NN was_VBD investigated_VBN ._SENT Accordingly_RB ,_, protein_NN lysates_NNS from_IN SiHa_NP cells_NNS treated_VBN with_IN low-dose_NN (_( 10-6_CD M_NN )_) or_CC high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP were_VBD evaluated_VBN by_IN Western_JJ immunoblotting_NN ._SENT ATRA_NNS at_IN a_DT concentration_NN of_IN 10-6_CD M_NP increased_VBD protein_NN levels_NNS of_IN IRF-1_NP at_IN a_DT peak_NN of_IN fourfold_RB 6_CD h_NN after_IN treatment_NN ,_, while_IN induction_NN of_IN IRF-1_JJ protein_NN by_IN 10-4_CD M_NP ATRA_NP was_VBD sustained_VBN ._SENT We_PP also_RB determined_VBD IRF-1_JJ protein_NN levels_NNS 24_CD h_NN after_IN treatment_NN with_IN various_JJ concentrations_NNS of_IN ATRA_NP ._SENT Apparently_RB ,_, induction_NN of_IN IRF-1_NP at_IN 24_CD h_NN was_VBD dose_NN dependent_JJ ;_: significant_JJ induction_NN occurred_VBN at_IN high_JJ doses_NNS ._SENT In_IN another_DT set_NN of_IN experiments_NNS ,_, SiHa_NP cells_NNS were_VBD transiently_RB transfected_VBN with_IN an_DT IRF-1_JJ expression_NN vector_NN ._SENT Using_VBG a_DT trypan_JJ blue_JJ exclusion_NN test_NN ,_, we_PP determined_VBD the_DT cell_NN number_NN 48_CD h_NN posttransfection_NN ._SENT The_DT results_NNS (_( representing_VBG the_DT mean_NN of_IN three_CD independent_JJ measurements_NNS in_IN which_WDT the_DT standard_JJ deviation_NN did_VBD not_RB exceed_VB 4_CD %_NN )_) showed_VBD that_IN IRF-1_JJ transfection_NN significantly_RB reduced_VBN cell_NN numbers_NNS ,_, to_TO 65_CD %_NN of_IN the_DT level_NN of_IN untreated_JJ control_NN cells_NNS ._SENT Also_RB ,_, transient_JJ transfection_NN of_IN an_DT antisense_NN IRF-1_JJ construct_NN abrogated_VBD ATRA-induced_JJ growth_NN arrest_NN ._SENT Prolonged_JJ induction_NN of_IN IRF-1_NP requires_VBZ STAT1_NP ._SENT |_SYM IRF-1_JJ mRNA_NN levels_NNS were_VBD increased_VBN only_RB moderately_RB and_CC transiently_RB after_IN treatment_NN with_IN ATRA_NP in_IN a_DT STAT1_NP knockout_NN cell_NN line_NN (_( U3A_NP )_) ,_, while_IN treatment_NN of_IN the_DT parental_JJ (_( STAT1_JJ wild-type_NN )_) line_NN (_( 2fTGH_JJ )_) with_IN ATRA_NP increased_VBD it_PP significantly_RB and_CC for_IN a_DT longer_JJR time_NN ._SENT Only_JJ high-dose_NN ATRA_NP induces_VBZ phosphorylation_NN of_IN STAT1_NP ._SENT |_SYM Considering_NP the_DT role_NN of_IN STAT1_NP in_IN regulation_NN of_IN IRF-1_JJ expression_NN ,_, we_PP determined_VBD the_DT phosphorylation_NN status_NN of_IN STAT1_NP after_IN ATRA_NP treatment_NN ._SENT Treatment_NN with_IN 10-6_CD M_NP ATRA_NP did_VBD not_RB affect_VB STAT1_JJ tyrosine_NN phosphorylation_NN ._SENT In_IN contrast_NN ,_, 10-4_CD M_NP ATRA_NP treatment_NN significantly_RB elevated_VBD STAT1_JJ tyrosine_NN phosphorylation_NN between_IN 3_CD to_TO 12_CD h_NN posttreatment_NN ._SENT STAT1_JJ levels_NNS ,_, however_RB ,_, remained_VBD unchanged_JJ during_IN ATRA_NP treatment_NN ._SENT NF-kappaB_NN binding_VBG to_TO an_DT oligonucleotide_NN from_IN the_DT IRF-1_JJ promoter_NN is_VBZ independent_JJ of_IN ATRA_NP concentrations_NNS ._SENT |_SYM IRF-1_JJ transcription_NN is_VBZ regulated_VBN via_IN NF-kappaB_NP sites_NNS in_IN the_DT IRF-1_JJ gene_NN promoter_NN ._SENT Accordingly_RB ,_, we_PP tested_VBD NF-kappaB_NP binding_VBG to_TO oligonucleotides_NNS corresponding_JJ to_TO NF-kappaB-binding_JJ sites_NNS in_IN the_DT IRF-1_JJ promoter_NN by_IN a_DT gel-shift_NN assay_NN ._SENT As_IN shown_VBN ,_, NF-kappaB_NP (_( mostly_RB the_DT p65-p50_JJ complex_NN )_) binding_VBG to_TO the_DT IRF-1_JJ promoter_NN was_VBD increased_VBN after_IN 30_CD min_NN by_IN both_DT low-_NN and_CC high-dose_NN ATRA_NP treatment_NN (_( Fig._NN and_CC B_NN )_) ._SENT STAT1_JJ binding_NN to_TO an_DT oligonucleotide_NN from_IN the_DT IRF-1_JJ promoter_NN depends_VBZ on_IN ATRA_NP concentration_NN ._SENT |_SYM IRF-1_JJ transcription_NN could_MD be_VB also_RB regulated_VBN via_IN GAS/SIE_NP sites_NNS in_IN the_DT IRF-1_JJ gene_NN promoter_NN ._SENT Accordingly_RB ,_, we_PP tested_VBD STAT1-binding_NP oligonucleotides_NNS corresponding_JJ to_TO a_DT GAS_JJ site_NN in_IN the_DT IRF-1_JJ promoter_NN by_IN a_DT gel-shift_NN assay_NN ._SENT In_IN the_DT extracts_VBZ of_IN ATRA-treated_JJ cells_NNS ,_, binding_VBG of_IN STAT1_NP to_TO a_DT GAS_JJ site_NN was_VBD observed_VBN only_RB after_IN high-dose_NN ,_, but_CC not_RB low-dose_NN ,_, ATRA_NP treatment_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Effects_NN of_IN ATRA_NP on_IN cell_NN growth_NN ._SENT Effects_NNS of_IN ATRA_NP on_IN cell_NN growth_NN ._SENT SiHa_NP cells_NNS were_VBD seeded_VBN in_IN a_DT multiwell_NN plate_NN and_CC treated_VBN with_IN either_DT low-dose_NN (_( 10-7_CD and_CC 10-6_CD M_NN )_) or_CC high-dose_NN (_( 10-5_CD and_CC 10-4_CD M_NN )_) ATRA_NP for_IN the_DT times_NNS indicated_VBD ._SENT An_DT MTT_NP assay_NN was_VBD employed_VBN to_TO determine_VB the_DT amounts_NNS of_IN viable_JJ cells_NNS ._SENT Results_NNS are_VBP shown_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( n_NN =_SYM 3_CD )_) ._SENT FIG._NN 2_CD ._SENT |_SYM Effects_NN of_IN ATRA_NP on_IN IRF-1_JJ protein_NN levels_NNS in_IN SiHa_NP cells_NNS ._SENT Effects_NNS of_IN ATRA_NP on_IN IRF-1_JJ protein_NN levels_NNS in_IN SiHa_NP cells_NNS ._SENT Confluent_JJ cultures_NNS of_IN SiHa_NP cells_NNS were_VBD treated_VBN with_IN either_DT low-dose_NN (_( 10-6_CD M_NN )_) or_CC high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP for_IN the_DT times_NNS indicated_VBD ._SENT Top_JJ ,_, Western_JJ immunoblotting_NN was_VBD performed_VBN on_IN the_DT total_JJ cell_NN lysate_NNS as_RB described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Bottom_JJ ,_, Densitometric_JJ results_NNS are_VBP expressed_VBN as_IN fold_NN change_NN to_TO the_DT untreated_JJ controls_NNS ._SENT Values_NNS are_VBP shown_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( n_NN =_SYM 3_CD )_) ._SENT FIG._NN 3_CD ._SENT |_SYM Dose-dependent_NP induction_NN of_IN IRF-1_NP by_IN ATRA_NP ._SENT Dose-dependent_JJ induction_NN of_IN IRF-1_NP by_IN ATRA_NP ._SENT Confluent_JJ cultures_NNS of_IN SiHa_NP cells_NNS were_VBD treated_VBN for_IN 24_CD h_NN with_IN various_JJ doses_NNS of_IN ATRA_NP as_RB indicated_VBD ._SENT Western_JJ immunoblotting_NN was_VBD performed_VBN on_IN the_DT total_JJ cell_NN lysate_NNS as_RB described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Densitometric_JJ results_NNS are_VBP expressed_VBN as_IN fold_NN change_NN to_TO the_DT untreated_JJ controls_NNS ._SENT Values_NNS are_VBP shown_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( n_NN =_SYM 3_CD )_) ._SENT FIG._NN 4_CD ._SENT |_SYM Prolonged_JJ induction_NN of_IN IRF-1_NP requires_VBZ STAT1_NP ._SENT Prolonged_JJ induction_NN of_IN IRF-1_NP requires_VBZ STAT1_NP ._SENT STAT1_JJ knockout_NN (_( U3A_NP )_) or_CC STAT1_NP wild-type_NP (_( 2fTGH_NP )_) cells_NNS were_VBD treated_VBN with_IN ATRA_NP (_( 10-6_CD M_NN )_) for_IN different_JJ time_NN points_NNS ._SENT IRF-1_JJ mRNA_NN levels_NNS were_VBD determined_VBN by_IN reverse_JJ transcription-PCR_NN together_RB with_IN the_DT constitutively_RB expressed_VBN G3PDH_NP ._SENT IRF-1_JJ levels_NNS are_VBP given_VBN as_IN ratios_NNS of_IN IRF-1/G3PDH_NP ._SENT Values_NNS are_VBP shown_VBN as_IN means_NN +-_NN standard_JJ deviations_NNS (_( n_NN =_SYM 3_CD )_) ._SENT FIG._NN 5_CD ._SENT |_SYM Effects_NN of_IN different_JJ doses_NNS of_IN ATRA_NP on_IN tyrosine_NN phosphorylation_NN of_IN STAT1_NP in_IN SiHa_NP cells_NNS ._SENT Effects_NNS of_IN different_JJ doses_NNS of_IN ATRA_NP on_IN tyrosine_NN phosphorylation_NN of_IN STAT1_NP in_IN SiHa_NP cells_NNS ._SENT Confluent_JJ cultures_NNS of_IN SiHa_NP cells_NNS were_VBD treated_VBN with_IN low-dose_NN (_( 10-6_CD M_NN )_) or_CC high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP for_IN the_DT times_NNS indicated_VBD ._SENT Western_JJ immunoblotting_NN was_VBD performed_VBN using_VBG anti-phosphoSTAT1_JJ (_( STAT1p_NP )_) as_RB well_RB as_IN anti-STAT1_JJ antibodies_NNS ._SENT Experimental_JJ data_NNS shown_VBN are_VBP representative_JJ of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 6_CD ._SENT |_SYM Effects_NN of_IN different_JJ doses_NNS of_IN ATRA_NP treatment_NN on_IN binding_VBG of_IN cellular_JJ proteins_NNS to_TO oligonucleotides_NNS representing_VBG NF-kappaB_NP or_CC GAS_NP sites_NNS of_IN the_DT IRF-1_JJ promoter_NN ._SENT Effects_NNS of_IN different_JJ doses_NNS of_IN ATRA_NP treatment_NN on_IN binding_VBG of_IN cellular_JJ proteins_NNS to_TO oligonucleotides_NNS representing_VBG NF-kappaB_NP or_CC GAS_NP sites_NNS of_IN the_DT IRF-1_JJ promoter_NN ._SENT Nuclear_NP extracts_VBZ from_IN SiHa_NP cells_NNS treated_VBN with_IN low-dose_NN (_( A_NP and_CC C_NP )_) or_CC high-dose_NN (_( B_NP and_CC D_NP )_) ATRA_NP were_VBD incubated_VBN with_IN labeled_VBN oligonucleotides_NNS representing_VBG the_DT NF-kappaB_NP (_( A_NP and_CC B_NP )_) or_CC GAS_NP (_( C_NP and_CC D_NP )_) binding_JJ sites_NNS of_IN the_DT IRF-1_JJ promoter_NN ,_, and_CC an_DT EMSA_NP was_VBD performed_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT In_IN panels_NNS A_NP and_CC B_NP we_PP showed_VBD only_RB the_DT 30-min_JJ time_NN point_NN that_WDT represented_VBD the_DT first_JJ appearance_NN of_IN NF-kappaB_NP binding_NN ._SENT STAT1_JJ binding_NN to_TO the_DT GAS_NP oligomer_NP (_( C_NP and_CC D_NP )_) appeared_VBD after_IN 6_CD h_NN of_IN treatment_NN ._SENT Next_JJ ,_, 100x_JJ cold_JJ ligand_NN was_VBD used_VBN to_TO demonstrate_VB specificity_NN of_IN both_DT probes_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Tetradecanoyl_NP phorbol_NN acetate_NN (TPA)-_NN or_CC gamma_NN interferon_NN (IFNgamma)-_NN treated_VBN cell_NN extracts_VBZ were_VBD used_VBN as_IN positive_JJ controls_NNS ._SENT Preincubations_NNS with_IN specific_JJ anti-NF-kappaB_NN p65_NN and_CC p50_NN or_CC STAT1_JJ antibodies_NNS were_VBD performed_VBN to_TO demonstrate_VB the_DT presence_NN of_IN these_DT proteins_NNS in_IN the_DT observed_JJ complexes_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Induction_NN of_IN IRF-1_JJ mRNA_NN and_CC the_DT consequent_JJ growth_NN inhibition_NN in_IN cervical_JJ squamous_JJ carcinoma_NN cells_NNS by_IN ATRA_NP have_VBP been_VBN demonstrated_VBN ._SENT Clinically_RB ,_, retinoids_NNS reversed_VBD or_CC suppressed_VBD low-grade_NN or_CC moderate-_NN to_TO high-grade_JJ cervical_JJ dysplasias_NNS but_CC were_VBD not_RB effective_JJ in_IN patients_NNS with_IN more_JJR advanced_JJ dysplasias_NNS ._SENT Although_IN immortalized_VBN keratinocytes_NNS are_VBP more_RBR sensitive_JJ to_TO growth_NN control_NN by_IN retinoids_NNS than_IN their_PP$ normal_JJ counterparts_NNS ,_, at_IN later_JJR stages_NNS transformed_VBD keratinocytes_NNS frequently_RB become_VBP resistant_JJ to_TO retinoids_NNS ._SENT SiHa_NP cervical_JJ squamous_JJ carcinoma_NN cells_NNS have_VBP been_VBN reported_VBN to_TO be_VB unresponsive_JJ to_TO retinoids_NNS ._SENT In_IN our_PP$ experiments_NNS ,_, SiHa_NP cells_NNS exhibited_VBD resistance_NN to_TO 10-7_CD to_TO 10-6_CD M_NP ATRA-induced_NP growth_NN inhibition_NN ,_, but_CC 10-5_CD M_NN and_CC especially_RB 10-4_CD M_NP ATRA_NP significantly_RB inhibited_VBD the_DT growth_NN of_IN SiHa_NP cells_NNS ._SENT A_DT hallmark_NN of_IN growth_NN inhibition_NN is_VBZ the_DT high_JJ expression_NN of_IN the_DT IRF-1_JJ gene_NN ._SENT Ultimately_RB ,_, this_DT induction_NN of_IN IRF-1_NP is_VBZ responsible_JJ for_IN the_DT observed_JJ growth_NN inhibition_NN of_IN target_NN cells_NNS ._SENT Introduction_NN of_IN an_DT IRF-1_JJ expression_NN vector_NN into_IN SiHa_NP cells_NNS caused_VBD growth_NN arrest(see_NN above_JJ )_) ._SENT Similarly_RB ,_, in_IN the_DT presence_NN of_IN an_DT antisense_NN IRF-1_JJ expression_NN plasmid_NN ,_, high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP did_VBD not_RB inhibit_VB cell_NN growth_NN (_( viable_JJ cells_NNS were_VBD at_IN 95_CD %_NN of_IN control_NN level_NN ,_, compared_VBN to_TO 60_CD %_NN with_IN ATRA_NP but_CC without_IN the_DT IRF-1_JJ expression_NN plasmid_NN )_) ._SENT IRF-1_JJ expression_NN was_VBD elevated_VBN in_IN ATRA-treated_JJ cells_NNS in_IN a_DT dose-dependent_JJ fashion_NN :_: low-dose_NN (_( 10-6_CD M_NP )_) ATRA_NP increased_VBD it_PP temporarily_RB ,_, while_IN high-dose_NN (_( 10-4M_NP )_) ATRA_NP caused_VBD a_DT sustained_JJ expression_NN of_IN IRF-1_NP (_( Fig._NN and_CC )_) ._SENT However_RB ,_, only_JJ high-dose_NN (_( 10-5_CD to_TO 10-4_CD M_NN )_) but_CC not_RB low-dose_NN (_( 10-7_CD to_TO 10-6_CD M_NN )_) ATRA_NP could_MD significantly_RB inhibit_VB cell_NN growth_NN in_IN vitro_NN ._SENT These_DT data_NNS strongly_RB suggested_VBD that_DT duration_NN of_IN IRF-1_JJ expression_NN is_VBZ critical_JJ for_IN cell_NN growth_NN inhibition_NN in_IN this_DT system_NN ._SENT Our_PP$ next_JJ set_NN of_IN experiments_NNS aimed_VBN to_TO determine_VB the_DT molecular_JJ events_NNS behind_IN this_DT dose-dependent_JJ induction_NN of_IN IRF-1_NP by_IN ATRA_NP ._SENT In_IN STAT1_JJ knockout_NN cells_NNS ,_, ATRA_NP moderately_RB and_CC temporarily_RB induced_VBN IRF-1_JJ mRNA_NN ,_, while_IN IRF-1_JJ induction_NN in_IN the_DT parental_JJ cell_NN line_NN (_( 2fTGH_NP )_) was_VBD long_RB lasting_JJ under_IN the_DT same_JJ conditions_NNS ._SENT Activation_NN (_( tyrosine_NN phosphorylation_NN )_) of_IN STAT1_NP occurred_VBD only_RB after_IN high-dose_NN (_( 10-4_CD M_NP )_) ,_, but_CC not_RB low-dose_NN (_( 10-6_CD M_NP )_) ,_, ATRA_NP treatment_NN in_IN SiHa_NP ,_, suggesting_VBG that_IN the_DT capability_NN of_IN high-dose_NN ATRA_NP to_TO activate_VB STAT1_NP was_VBD responsible_JJ for_IN the_DT long-lasting_JJ activation_NN of_IN IRF-1_JJ expression_NN and_CC consequent_JJ inhibition_NN of_IN cell_NN growth_NN ._SENT Interestingly_RB ,_, the_DT kinetics_NN of_IN this_DT tyrosine_NN phosphorylation_NN was_VBD delayed_VBN (_( 3_CD to_TO 13_CD h_NN )_) compared_VBN to_TO the_DT immediate-early_JJ (_( 5_CD to_TO 15_CD min_NN )_) phosphorylation_NN by_IN cytokines_NNS ._SENT Similarly_RB ,_, binding_VBG of_IN the_DT activated_VBN STAT1_NP to_TO the_DT GAS_JJ site_NN was_VBD a_DT late_JJ event_NN (_( 6_CD h_NN )_) ._SENT We_PP observed_VBD that_IN ATRA_NP treatment_NN --_: -at_NN both_CC 10-6_CD and_CC 10-4_CD M_NP concentrations_NNS --_: -induced_JJ binding_NN of_IN NF-kappaB_NP to_TO a_DT double-stranded_JJ oligonucleotide_NN originating_VBG from_IN the_DT IRF-1_JJ promoter_NN ,_, similar_JJ to_TO that_DT described_VBN by_IN others_NNS ._SENT However_RB ,_, binding_VBG of_IN STAT1_NP to_TO its_PP$ cognate_JJ GAS_NN elements_NNS in_IN the_DT IRF-1_JJ promoter_NN was_VBD observed_VBN only_RB after_IN high-dose_NN (_( 10-4_CD M_NP )_) ATRA_NP treatment_NN ,_, suggesting_VBG that_IN STAT1_NP activation_NN was_VBD responsible_JJ for_IN the_DT sustained_JJ IRF-1_JJ expression_NN ._SENT Phosphorylation_NN of_IN STAT1_NP and_CC its_PP$ binding_NN to_TO the_DT IRF-1_JJ promoter_NN occurred_VBN with_IN delayed_JJ kinetics_NNS compared_VBN to_TO IRF-1_JJ activation_NN via_IN NF-kappaB_NP binding_NN ._SENT The_DT effects_NNS of_IN GAS_NP and_CC NF-kappaB_NP sites_NNS on_IN the_DT activity_NN of_IN the_DT IRF-1_JJ promoter_NN might_MD be_VB synergistic_JJ and_CC could_MD be_VB accountable_JJ for_IN the_DT long-lasting_JJ activation_NN of_IN IRF-1_JJ expression_NN ._SENT It_PP has_VBZ been_VBN postulated_VBN that_IN retinoids_NNS directly_RB increase_VB the_DT expression_NN of_IN transcription_NN factors_NNS (_( STAT1_NP or_CC IRF-1_NP )_) that_WDT play_VBP key_JJ roles_NNS in_IN JAK-STAT_NP signaling_VBG ,_, thereby_RB restoring_VBG interferon_NN (_( IFN_NP )_) sensitivity_NN ._SENT Our_PP$ data_NNS suggest_VBP that_IN ATRA_NP could_MD restore_VB sensitivity_NN to_TO itself_PP by_IN a_DT dose-dependent_JJ induction_NN of_IN STAT1_NP ,_, resulting_VBG in_IN a_DT sustained_JJ activation_NN of_IN the_DT IRF-1_JJ signal_NN that_WDT might_MD be_VB critical_JJ in_IN determining_VBG downstream_JJ cellular_JJ responses_NNS ._SENT The_DT downstream_JJ targets_NNS might_MD include_VB the_DT activation_NN of_IN apoptotic_JJ events_NNS associated_VBN with_IN the_DT IRF-1/CAS_NP pathway_NN or_CC NF-kB_NN induction_NN or_CC both_DT ._SENT The_DT role_NN of_IN these_DT pathways_NNS in_IN high-dose_NN ATRA-induced_JJ inhibition_NN of_IN cell_NN growth_NN ,_, however_RB ,_, needs_VBZ further_JJR evaluation_NN ._SENT 